特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
740502

世界の急性骨髄性白血病市場の2029年までの予測:化学療法、標的治療、シタラビン、ダウノルビシン、Midostaurin、Enasidenib

Global Acute Myeloid Leukaemia Market Forecast to 2029: Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib

出版日: | 発行: Visiongain Ltd | ページ情報: 英文 149 Pages | 納期: 即日から翌営業日

価格
価格表記: GBPを日本円(税抜)に換算
本日の銀行送金レート: 1GBP=143.04円

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

世界の急性骨髄性白血病市場の2029年までの予測:化学療法、標的治療、シタラビン、ダウノルビシン、Midostaurin、Enasidenib
出版日: 2019年10月31日
発行: Visiongain Ltd
ページ情報: 英文 149 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の急性骨髄性白血病市場は今後CAGR13%で拡大すると見込まれています。2018年は、化学療法セグメントが市場全体の32%のシェアを獲得しました。

当レポートでは、世界の急性骨髄性白血病市場について調査し、市場の動向と予測、市場規模、主要参入企業、地域別動向についてまとめています。

第1章 報告書の概要

第2章 市場概要

  • イントロダクション
  • 疫学
  • 治療法

第3章 薬剤タイプ別市場予測

  • 化学療法
  • 標的治療
  • その他

第4章 地域別市場予測

  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ・中東・アフリカ

第5章 企業プロファイル

  • 第一三共株式会社
  • Celgene Corporation
  • Teva Pharmaceuticals
  • エーザイ株式会社
  • Novartis AG
  • GlaxoSmithKline Inc
  • Sunesis Pharmaceuticals
  • Clavis Pharma ASA
  • F. Hoffman-La Roche Ltd.
  • Bristol-Myers Squibb

第6章 定性分析

  • 市場促進因子
  • 市場阻害因子
  • 市場の機会

第7章 業界分析

第8章 パイプラインと治験分析

  • パイプライン舟s期
  • 低分子標的治療
  • イソクエン酸脱水素酵素 阻害剤
  • モノクローナル抗体
  • 治験

第9章 結論

図表

List of Tables

  • Table 2.1 Global Acute Myeloid Leukemia, Subtypes, Based on FAB Classification
  • Table 2.2 Global Acute Myeloid Leukemia, Subtypes, Based on WHO Classification
  • Table 3.1. Global Acute Myeloid Leukemia Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 3.2. Global AML Therapeutics Market - Based on type (in %), 2018-2029
  • Table 3.3 Global AML Chemotherapy Drug Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 3.4. Cytarabine Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 3.5 Daunorubicin Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 3.6. Other Chemotherapy Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 3.7 Targeted Therapy Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 3.8 Midostaurin Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 3.9 Enasidenib Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 3.10 Other Targeted Therapy Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.1. North America AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.2 North America AML therapeutics Drug Market by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.3. USA AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.4. USA AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Table 4.5. USA AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.6. Canada AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.7. Canada AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.8. Mexico AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.9. Mexico AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.10. Europe AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.11. Europe AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.12 Germany AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.13 Germany AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.14 UK AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.15 UK AML Therapeutics Market by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.16 Italy AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.17. Italy AML Therapeutics Market Forecast by Type Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.18 France AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.19. France AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.20. Spain AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.21. Spain AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.22. Rest of Europe AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.23. ROE AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.24. Asia Pacific AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.25. Asia Pacific AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.26. Japan AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.27. Japan AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.28. China AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.29. China AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.30. India AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.31. India AML Therapeutics Market Forecast by Type: (Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.32. Australia AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.33. Australia AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.34. Rest of Asia Pacific AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.35. Rest of Asia Pacific AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.36. LAMEA AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.37. LAMEA AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.38. GCC AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.39. GCC AML Therapeutics Market by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.40. Brazil AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.41. Brazil AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.42. South Africa AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.43. South Africa AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.44. Rest of LAMEA AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.45. Rest of LAMEA AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 5.1 Daiichi Sankyo: Revenue ($m), R&D ($m), 2016-2018
  • Table 5.2 Daiichi Sankyo Recent Developments
  • Table 5.3 Celgene: Revenue ($m), R&D ($m), 2016-2018
  • Table 5.4 Celgene Recent Developments
  • Table 5.5 TEVA Operating Segments
  • Table 5.6 TEVA: Revenue ($m), R&D ($m), 2016-2018
  • Table 5.7 TEVA Recent Developments
  • Table 5.8 Eisai Operating Segments
  • Table 5.9 Eisai Revenue ($m), R&D ($m), 2016-2018
  • Table 5.10 Novartis Operating Segments
  • Table 5.11 Novartis: Revenue ($m), R&D ($m), 2016-2018
  • Table 5.12 Novartis Recent Developments
  • Table 5.13 GSK Operating Segments
  • Table 5.14 GSK: Revenue ($m), R&D ($m), 2016-2018
  • Table 5.15 Sunesis: Revenue ($m), R&D ($m), 2016-2018
  • Table 5.16 Roche Operating Segments
  • Table 5.17 Roche: Revenue ($m), R&D ($m), 2016-2018
  • Table 5.18 Roche Recent Developments
  • Table 5.19 Bristol-Myers: Revenue ($m), 2016-2018
  • Table 8.1 AML Drugs in the Pipeline: Agent, MOA, Clinical Trial Code
  • Table 8.2 Completed Clinical Trials for AML
  • Table 8.3 List of Recruiting Clinical Trials for AML
  • Table 9.1: Global Acute Myeloid Leukemia Market by Treatment Type: Revenue ($m), 2019, 2023, 2029

List of Figures

  • Figure 2.1 Percentage of estimated new Leukemia cases in 2018 among all blood cancer cases, a global perspective
  • Figure 2.2 Prevalence of Acute Myeloid Leukemia in the population based on age (2018)
  • Figure 3.1. Global Acute Myeloid Leukemia Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 3.2. Global AML Therapeutics Market (% Share) - Based on Type, 2018
  • Figure 3.3 Global AML Chemotherapy Drug Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 3.4. Global AML Chemotherapy Drugs (% Share) - Based on types 2018
  • Figure 3.5. Cytarabine Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 3.6 Daunorubicin Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 3.7. Other Chemotherapy Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 3.8. Targeted Therapy Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 3.9. Midostaurin Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 3.10 Enasidenib Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 3.11 Other Targeted Therapy Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.1. Global Percentage Share of AML Therapeutics Market by Region: % Share, 2019
  • Figure 4.2. Global Percentage Share of AML Therapeutics Market by Region: % Share, 2023
  • Figure 4.3. Global Percentage Share of AML Therapeutics Market by Region: % Share, 2029
  • Figure 4.4. North America AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.5 North America AML Therapeutics Market by Country: % Share, 2019
  • Figure 4.6. USA AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029
  • Figure 4.7. Canada AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.8. Canada AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029
  • Figure 4.9. Mexico AML therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.10 Mexico AML therapeutic Market Forecast by Type: Revenue ($m), 2019-2029
  • Figure 4.11. Europe AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.12. Europe AML Therapeutics Market by Region: % Share, 2019
  • Figure 4.13. Germany AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.14 Germany AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029
  • Figure 4.15. UK AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.16 UK AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029
  • Figure 4.17. Italy AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.18. Italy AML Therapeutics Market Forecast: Revenue ($m), 2019-2029
  • Figure 4.19 France AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.20. France AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029
  • Figure 4.21 Spain AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.22. Spain AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029
  • Figure 4.23. Rest of Europe AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.24. ROE AML Therapeutics Market by Type: Revenue ($m), 2019-2029
  • Figure 4.25. Asia Pacific AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.26. Asia Pacific AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029
  • Figure 4.27. Asia Pacific AML Therapeutics Market by Country: % Share, 2019
  • Figure 4.28. Japan AML therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.29. Japan AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029
  • Figure 4.30. China AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.31. China AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029
  • Figure 4.32. India AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.33. India AML Therapeutics Market by Type: Revenue ($m), 2019-2029
  • Figure 4.34. Australia AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.35. Australia AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029
  • Figure 4.36. Rest of Asia Pacific AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.37. Rest of Asia Pacific AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029
  • Figure 4.38. LAMEA AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.39. LAMEA AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029
  • Figure 4.40 LAMEA AML Therapeutics Market by Country: % Share, 2019
  • Figure 4.41. GCC AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.42. GCC AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029
  • Figure 4.43 Brazil AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.44. Brazil AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029
  • Figure 4.45. South Africa AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.46. South Africa AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029
  • Figure 4.47. Rest of LAMEA AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.48. Rest of LAMEA AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029
  • Figure 9.1: Global Acute Myeloid Leukemia Market by Treatment Type: Revenue ($m), 2019, 2023, 2029

List of Companies Mentioned in the Report

  • AbbVie
  • Agios Pharmaceuticals, Inc.
  • Ambit Biosciences Corporation
  • Amgen
  • Animas Corporation
  • Astex
  • B. Braun Melsungen AG
  • Baxter, Becton, Dickinson and Company (BD)
  • Bayer
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company (Bristol-Myers)
  • Celator Pharmaceuticals, Inc.
  • Celgene
  • Clavis Pharma ASA (Clavis Pharma)
  • Cyclacel
  • Daiichi Pharmaceutical
  • Daiichi Sankyo
  • Eisai Co., Ltd. (Eisai)
  • F. Hoffmann-La Roche Ltd. (Roche)
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline plc (GSK)
  • GLOBOCAN
  • Hospira
  • Medtronic
  • Moog Inc.
  • NeoMed
  • Norsk Hydro
  • Novartis
  • Onyx Pharmaceuticals
  • Sankyo
  • Seattle Genetics
  • Smiths Group Plc.,
  • Sunesis Pharmaceuticals, Inc. (Sunesis)
  • TEVA Pharmaceutical Industries Limited (TEVA)
  • List of Organizations Mentioned in the Report American Cancer Organization
  • Baylor Scott and White Research Institute
  • Benaroya Research Institute at Virginia Mason
  • Beth Israel Deaconess Medical Center
  • Breslin Cancer Center
  • Center for Blood Disorders and Stem Cell Transplantation
  • Charles A. Sammons Cancer Center
  • Columbia University Medical
  • Dana Farber Cancer Institute
  • Duke Cancer Center
  • European Commission
  • Fred Hutchinson Cancer Research Center
  • Health Canada
  • Herbert Irving Comprehensive Cancer Center
  • Institute of Hematology & Blood Diseases Hospital,Tianjin
  • James Graham Brown Cancer Center
  • Legacy Emanuel Hospital & Health Center
  • Mary Babb Randolph Cancer Center
  • Massachusetts general Hospital
  • Mayo Clinic
  • MD Anderson Cancer Center
  • Medical College of Wisconsin Cancer Center
  • Medizinische Klinik und Poliklinik I
  • Memorial Sloan Kettering Cancer Center
  • Michigan State University
  • Nantes University Hospital
  • National Cancer Institute
  • New Jersey Hematology Oncology Associates
  • Northwestern University
  • Ochsner Medical Center
  • Penn State Hershey Cancer Institute-Clinical Trials Office
  • Perelman Center for Advanced Medicine
  • Princess Margaret Hospital
  • St. Francis Cancer Center
  • St. Joseph Mercy Hospital
  • St. Vincent's Comprehensive Cancer Center
  • Swedish Cancer Institute
  • The Gayle and Tom Benson Cancer Center
  • The University of Hong Kong
  • The University of Iowa The University of Texas MD Anderson Cancer Center
  • Thomas Jefferson University
  • U.S. Food and Drug Administration (FDA)
  • UCLA Medical Center, Division of Hematology/Oncology
  • University Hospital, Caen
  • University of Kansas Cancer Center
  • University of Kansas Medical Center Research Institute
  • University of Kentucky
  • University of Louisville
  • University of Michigan Health System
  • University of Pennsylvania
  • University of Texas M.D. Anderson Cancer Center
  • VA Caribbean Healthcare System
  • Weill Cornell Medical College
  • Weill Medical College of Cornell University
  • West Virginia University
  • World Health Organization (WHO)
目次
Product Code: PHA0576

The global acute myeloid leukaemia market is estimated to grow at a CAGR of 13% in the first half of the forecast period. In 2018, the chemotherapy segment held 32% share of the global acute myeloid leukaemia market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 149-page report you will receive 143 charts- all unavailable elsewhere.

The 149-page report provides clear detailed insight into the acute myeloid leukaemia market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Acute Myeloid Leukaemia Market forecast to 2029
  • Forecast of the Global Acute Myeloid Leukaemia market by Treatment Type and Product Type:
  • Chemotherapy: Cytarabine, Daunorubicin, Others
  • Targeted Therapy: Midostaurin, Enasidenib, Others
  • This report provides individual revenue forecasts to 2029 for these regional and national markets:
  • North America: US, Canada, and Mexico
  • Europe: Germany, France, United Kingdom, Italy, Spain and rest of Europe
  • Asia-Pacific: Japan, China, India, Australia and Rest of Asia-Pacific
  • LAMEA: GCC, Brazil, South Africa, Rest of LAMEA

image1

Each national market forecast is further segmented by type: chemotherapy and targeted therapy.

  • Our study discusses the selected leading companies that are the major players in the acute myeloid leukaemia market:
  • Bristol-Myers Squibb Company
  • Celgene
  • Clavis Pharma ASA
  • Daiichi Sankyo
  • Eisai
  • GSK
  • Novartis
  • Roche
  • Sunesis Pharmaceuticals
  • Teva
  • This report discusses factors that drive and restrain the acute myeloid leukaemia market. This report also discusses the opportunities that can be tapped in this market.
  • This report discusses Porter's Five Forces analysis of the acute myeloid leukaemia market.
  • This report also discusses several new agents that are in development for the treatment of acute myeloid leukaemia.
  • Key questions answered in this report:
  • How is the Acute myeloid leukemia market evolving?
  • What are the drivers and restraints for the growth of the acute myeloid leukemia market?
  • What are the market shares of each segment of the overall acute myeloid leukemia market in 2019?
  • How will each acute myeloid leukemia submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2029?
  • How will the market shares for each acute myeloid leukemia submarket develop from 2019 to 2029?
  • What is the value of the leading acute myeloid leukemia segments in important regions of the world?
  • What will be the main driver for the overall market from 2019 to 2029?
  • How will political and regulatory factors influence the regional markets and submarkets?
  • How will the market shares of the national markets change by 2029 and which geographical region will lead the market by 2029?
  • Who are the leading players and what are their prospects over the forecast period?
  • How will the industry evolve during the period between 2019 and 2029?

Visiongain's study is intended for anyone requiring commercial analyses for the acute myeloid leukaemia market. You find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Global Leukemia Market Overview
  • 1.2 Market Definition and Scope
  • 1.3 Why you should read this report?
  • 1.4 How the report delivers?
  • 1.5 Key Questions Answered in this Report
  • 1.6 Who is the report for?
  • 1.7 Report and Analysis Method
  • 1.8 Frequently Asked Questions
  • 1.9 Some Associated Reports
  • 1.10 About Visiongain

2. Acute Myeloid Leukemia Market Overview

  • 2.1 Introduction
    • 2.1.1 French-American-British (FAB) classification
    • 2.1.2 WHO Classification of AML
  • 2.2 Epidemiology of AML
  • 2.3 Treatment for AML
    • 2.3.1 Medication Overview

3. Global Acute Myeloid Leukemia Market Forecast to 2029 - Based on Drug Type

  • 3.1 Chemotherapy Based AML Therapeutics Market, 2019-2029
    • 3.1.1 Cytarabine
    • 3.1.2 Daunorubicin
    • 3.1.3 Other Chemotherapy Drugs
  • 3.2 Targeted therapy Market for AML Therapeutics - 2019-2029
    • 3.2.1 Midostaurin
    • 3.2.2 Enasidenib
    • 3.2.3 Other targeted therapy
  • 3.3 Other drugs used in the treatment of AML

4. Global AML Therapeutics Market Forecast to 2029 - Regional and National Market

  • 4.1 North America AML Therapeutics Market Forecast, 2019-2029
    • 4.1.1 USA AML Therapeutic Market Forecast, 2019-2029
    • 4.1.2 Canada AML Therapeutic Market Forecast, 2019-2029
    • 4.1.3 Mexico AML Therapeutic Market Forecast, 2019-2029
  • 4.2 Europe AML Therapeutics Market Forecast, 2019-2029
    • 4.2.1 Germany AML Therapeutics Market Forecast, 2019-2029
    • 4.2.2 UK AML Therapeutics Market Forecast, 2019-2029
    • 4.2.3 Italy AML therapeutics Market Forecast, 2019-2029
    • 4.2.4 France AML Therapeutics Market Forecast, 2019-2029
    • 4.2.5 Spain AML Therapeutics Market, 2019-2029
    • 4.2.6 Rest of Europe AML Therapeutics Market Forecast, 2019-2029
  • 4.3 Asia Pacific AML Therapeutics Market Forecast, 2019-2029
    • 4.3.1 Japan AML Therapeutics Market Forecast, 2019-2029
    • 4.3.2 China AML Therapeutics Market Forecast, 2019-2029
    • 4.3.3 India AML Therapeutics Market Forecast, 2019-2029
    • 4.3.4 Australia AML Therapeutics Market Forecast, 2019-2029
    • 4.3.5 Rest of Asia Pacific AML Therapeutic Market Forecast, 2019-2029
  • 4.4 Latin America and Middle East Africa AML Therapeutics Market Forecast, 2019-2029
    • 4.4.1 GCC AML Therapeutics Market Forecast, 2019-2029
    • 4.4.2 Brazil AML Therapeutics Market Forecast, 2019-2029
    • 4.4.3 South Africa AML Therapeutics Market Forecast, 2019-2029
    • 4.4.4 Rest of LAMEA AML Therapeutics Market, 2019-2029

5. Company Profiles

  • 5.1 Daiichi Sankyo
    • 5.1.1 Company Overview
    • 5.1.2 Financial Overview
    • 5.1.3 Recent Strategic Developments
  • 5.2 Celgene Corporation
    • 5.2.1 Company Overview
    • 5.2.2 Operational Segments
    • 5.2.3 Financial Overview
    • 5.2.4 Recent Developments
  • 5.3 Teva Pharmaceuticals
    • 5.3.1 Company Profile
    • 5.3.2 Operational Segments
    • 5.3.3 Financial Highlights
    • 5.3.4 Recent Developments
  • 5.4 Eisai., Co. Ltd.
    • 5.4.1 Company Overview
    • 5.4.2 Operational Segments
    • 5.4.3 Financial Overview
  • 5.5 Novartis AG
    • 5.5.1 Company Profile
    • 5.5.2 Operational Segments
    • 5.5.3 Financial Highlights
    • 5.5.4 Recent Developments
  • 5.6 GlaxoSmithKline Inc
    • 5.6.1 Company Overview
    • 5.6.2 Operating Segments
    • 5.6.3 Financial Highlights
  • 5.7 Sunesis Pharmaceuticals
    • 5.7.1 Company Profile
    • 5.7.2 Operational Segments
    • 5.7.3 Financial Overview
  • 5.8 Clavis Pharma ASA
    • 5.8.1 Company Profile
  • 5.9 F. Hoffman-La Roche Ltd.
    • 5.9.1 Company Profile
    • 5.9.2 Operational Segments
    • 5.9.3 Financial Analysis
    • 5.9.4 Recent Strategic Development
  • 5.10 Bristol-Myers Squibb
    • 5.10.1 Company Profile
    • 5.10.2 Financial Overview

6. Acute Myeloid Leukemia: Qualitative Analysis

  • 6.1. Market Drivers
    • 6.1.1 The rise in Cases of Chronic Diseases
    • 6.1.2 Research for Innovative Therapeutics
    • 6.1.3 Increase in the geriatric population
  • 6.2 Market Restraints
    • 6.2.1 The adverse effect of the treatment
  • 6.3 Market Opportunities
    • 6.3.1 Unmet Oncological Demand
    • 6.3.2 Untapped Opportunities in developing countries

7. Industry Analysis of the Market Players (Porter's Five Force Analysis)

  • 7.1 Bargaining Power of Suppliers
  • 7.2 The threat of New Entrants
  • 7.3 The threat of Substitute for Product
  • 7.4 Bargaining Power of Buyers
  • 7.5 Bargaining Power of Suppliers

8. Pipeline and Clinical trial Analysis

  • 8.1 Pipeline Analysis
    • 8.1.1 Vosaroxin (Sunesis Pharmaceuticals)
    • 8.1.2 CPX-351 (Celator Pharmaceuticals)
    • 8.1.3 Sepacitabine (Cyclacel)
    • 8.1.4 SGI-110 (Astex)
  • 8.2 Small Molecule Targeted Therapy
    • 8.2.1 Volasertib (Boehringer Ingelheim)
  • 8.3 Isocitrate Dehydrogenase Inhibitor
    • 8.3.1 ABT -199s (AbbVie, Roche)
    • 8.3.2 FLT3 Inhibitors
    • 8.3.3 Sorafenib (Bayer, Onyx Pharmaceuticals)
    • 8.3.4 Midostaurin (Novartis)
    • 8.3.5 Quizartinib (Daiichi Sankyo)
  • 8.4 Monoclonal Antibodies
    • 8.4.1 SGN-33A (Seattle Genetics)
    • 8.4.2 AMG-330 (Amgen)
  • 8.5 Clinical Trials

9. Conclusion

Appendices

  • Associated Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.